Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer

Dong Joo Kim, Tae Il Kim, Jung Hoo Suh, Yong Suk Cho, Sung Kwan Shin, Jin Kyung Kang, Nam Kyu Kim, Won Ho Kim

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

To compare, in terms of compliance, toxicity, quality of life (QOL) and efficacy, intravenous 5-fluorouracil plus folinic acid with oral tegafur-uracil plus folinic acid as postoperative adjuvant chemotherapy after curative resection in patients with Dukes' stage B2 and C2 colon cancer. Among all patients with adenocarcinoma of the colon operated on between July 1997 and June 1999, 122 with Dukes' stage B2 or C2 colon cancer were enrolled in this study. Fifty-three patients were treated with intravenous 5-fluorouracil plus folinic acid (5-FU group) and 69 with oral tegafur-uracil plus folinic acid (UFT group). Compliance, toxicity, QOL and efficacy were evaluated. Compared with the 5-FU group, patients in the UFT group experienced a lower incidence of grade 1 toxicity. The incidences of grade 2-4 toxicity were similar in the two treatment groups. However, severe toxicity (grade 3 or 4) was rare in both groups. A steady and significant increase of the QOL score, both during and after therapy, was evident in both groups suggesting that chemotherapy is quite tolerable and does not deteriorate the patients' QOL. At the median follow-up duration of 28 months, the survival rate and disease free survival rate for the UFT and 5-FU groups were 94.9% vs. 92.5% and 87.5% vs. 84.1%, respectively (p>0.05). These data suggest that oral tegafur-uracil modulated with oral folinic acid as an adjuvant chemotherapy in patients with Dukes' stage B2 and C2 colon cancer may be a good alternative to infusional 5- fluorouracil.

Original languageEnglish
Pages (from-to)665-675
Number of pages11
JournalYonsei medical journal
Volume44
Issue number4
DOIs
Publication statusPublished - 2003 Aug 30

Fingerprint

Tegafur
Uracil
Leucovorin
Adjuvant Chemotherapy
Fluorouracil
Colonic Neoplasms
Quality of Life
Compliance
Survival Rate
Incidence
Disease-Free Survival
Colon
Adenocarcinoma
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kim, Dong Joo ; Kim, Tae Il ; Suh, Jung Hoo ; Cho, Yong Suk ; Shin, Sung Kwan ; Kang, Jin Kyung ; Kim, Nam Kyu ; Kim, Won Ho. / Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer. In: Yonsei medical journal. 2003 ; Vol. 44, No. 4. pp. 665-675.
@article{4d82d3d8b94b4996b1828abdc16a05c2,
title = "Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer",
abstract = "To compare, in terms of compliance, toxicity, quality of life (QOL) and efficacy, intravenous 5-fluorouracil plus folinic acid with oral tegafur-uracil plus folinic acid as postoperative adjuvant chemotherapy after curative resection in patients with Dukes' stage B2 and C2 colon cancer. Among all patients with adenocarcinoma of the colon operated on between July 1997 and June 1999, 122 with Dukes' stage B2 or C2 colon cancer were enrolled in this study. Fifty-three patients were treated with intravenous 5-fluorouracil plus folinic acid (5-FU group) and 69 with oral tegafur-uracil plus folinic acid (UFT group). Compliance, toxicity, QOL and efficacy were evaluated. Compared with the 5-FU group, patients in the UFT group experienced a lower incidence of grade 1 toxicity. The incidences of grade 2-4 toxicity were similar in the two treatment groups. However, severe toxicity (grade 3 or 4) was rare in both groups. A steady and significant increase of the QOL score, both during and after therapy, was evident in both groups suggesting that chemotherapy is quite tolerable and does not deteriorate the patients' QOL. At the median follow-up duration of 28 months, the survival rate and disease free survival rate for the UFT and 5-FU groups were 94.9{\%} vs. 92.5{\%} and 87.5{\%} vs. 84.1{\%}, respectively (p>0.05). These data suggest that oral tegafur-uracil modulated with oral folinic acid as an adjuvant chemotherapy in patients with Dukes' stage B2 and C2 colon cancer may be a good alternative to infusional 5- fluorouracil.",
author = "Kim, {Dong Joo} and Kim, {Tae Il} and Suh, {Jung Hoo} and Cho, {Yong Suk} and Shin, {Sung Kwan} and Kang, {Jin Kyung} and Kim, {Nam Kyu} and Kim, {Won Ho}",
year = "2003",
month = "8",
day = "30",
doi = "10.3349/ymj.2003.44.4.665",
language = "English",
volume = "44",
pages = "665--675",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "4",

}

Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer. / Kim, Dong Joo; Kim, Tae Il; Suh, Jung Hoo; Cho, Yong Suk; Shin, Sung Kwan; Kang, Jin Kyung; Kim, Nam Kyu; Kim, Won Ho.

In: Yonsei medical journal, Vol. 44, No. 4, 30.08.2003, p. 665-675.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer

AU - Kim, Dong Joo

AU - Kim, Tae Il

AU - Suh, Jung Hoo

AU - Cho, Yong Suk

AU - Shin, Sung Kwan

AU - Kang, Jin Kyung

AU - Kim, Nam Kyu

AU - Kim, Won Ho

PY - 2003/8/30

Y1 - 2003/8/30

N2 - To compare, in terms of compliance, toxicity, quality of life (QOL) and efficacy, intravenous 5-fluorouracil plus folinic acid with oral tegafur-uracil plus folinic acid as postoperative adjuvant chemotherapy after curative resection in patients with Dukes' stage B2 and C2 colon cancer. Among all patients with adenocarcinoma of the colon operated on between July 1997 and June 1999, 122 with Dukes' stage B2 or C2 colon cancer were enrolled in this study. Fifty-three patients were treated with intravenous 5-fluorouracil plus folinic acid (5-FU group) and 69 with oral tegafur-uracil plus folinic acid (UFT group). Compliance, toxicity, QOL and efficacy were evaluated. Compared with the 5-FU group, patients in the UFT group experienced a lower incidence of grade 1 toxicity. The incidences of grade 2-4 toxicity were similar in the two treatment groups. However, severe toxicity (grade 3 or 4) was rare in both groups. A steady and significant increase of the QOL score, both during and after therapy, was evident in both groups suggesting that chemotherapy is quite tolerable and does not deteriorate the patients' QOL. At the median follow-up duration of 28 months, the survival rate and disease free survival rate for the UFT and 5-FU groups were 94.9% vs. 92.5% and 87.5% vs. 84.1%, respectively (p>0.05). These data suggest that oral tegafur-uracil modulated with oral folinic acid as an adjuvant chemotherapy in patients with Dukes' stage B2 and C2 colon cancer may be a good alternative to infusional 5- fluorouracil.

AB - To compare, in terms of compliance, toxicity, quality of life (QOL) and efficacy, intravenous 5-fluorouracil plus folinic acid with oral tegafur-uracil plus folinic acid as postoperative adjuvant chemotherapy after curative resection in patients with Dukes' stage B2 and C2 colon cancer. Among all patients with adenocarcinoma of the colon operated on between July 1997 and June 1999, 122 with Dukes' stage B2 or C2 colon cancer were enrolled in this study. Fifty-three patients were treated with intravenous 5-fluorouracil plus folinic acid (5-FU group) and 69 with oral tegafur-uracil plus folinic acid (UFT group). Compliance, toxicity, QOL and efficacy were evaluated. Compared with the 5-FU group, patients in the UFT group experienced a lower incidence of grade 1 toxicity. The incidences of grade 2-4 toxicity were similar in the two treatment groups. However, severe toxicity (grade 3 or 4) was rare in both groups. A steady and significant increase of the QOL score, both during and after therapy, was evident in both groups suggesting that chemotherapy is quite tolerable and does not deteriorate the patients' QOL. At the median follow-up duration of 28 months, the survival rate and disease free survival rate for the UFT and 5-FU groups were 94.9% vs. 92.5% and 87.5% vs. 84.1%, respectively (p>0.05). These data suggest that oral tegafur-uracil modulated with oral folinic acid as an adjuvant chemotherapy in patients with Dukes' stage B2 and C2 colon cancer may be a good alternative to infusional 5- fluorouracil.

UR - http://www.scopus.com/inward/record.url?scp=0041379123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041379123&partnerID=8YFLogxK

U2 - 10.3349/ymj.2003.44.4.665

DO - 10.3349/ymj.2003.44.4.665

M3 - Article

C2 - 12950123

AN - SCOPUS:0041379123

VL - 44

SP - 665

EP - 675

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 4

ER -